| # | Title | Journal | Year | Citations |
|---|
| 1 | Recent advances with liposomes as pharmaceutical carriers | Nature Reviews Drug Discovery | 2005 | 4,338 |
| 2 | Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? | Nature Reviews Drug Discovery | 2009 | 4,327 |
| 3 | Nanoparticle therapeutics: an emerging treatment modality for cancer | Nature Reviews Drug Discovery | 2008 | 3,710 |
| 4 | MicroRNA therapeutics: towards a new era for the management of cancer and other diseases | Nature Reviews Drug Discovery | 2017 | 3,558 |
| 5 | Can the pharmaceutical industry reduce attrition rates? | Nature Reviews Drug Discovery | 2004 | 3,510 |
| 6 | Therapeutic potential of resveratrol: the in vivo evidence | Nature Reviews Drug Discovery | 2006 | 3,283 |
| 7 | Cellular processing of platinum anticancer drugs | Nature Reviews Drug Discovery | 2005 | 3,194 |
| 8 | Engineering precision nanoparticles for drug delivery | Nature Reviews Drug Discovery | 2021 | 3,154 |
| 9 | Strategies in the design of nanoparticles for therapeutic applications | Nature Reviews Drug Discovery | 2010 | 3,124 |
| 10 | Targeting multidrug resistance in cancer | Nature Reviews Drug Discovery | 2006 | 3,098 |
| 11 | How many drug targets are there? | Nature Reviews Drug Discovery | 2006 | 3,073 |
| 12 | The dawning era of polymer therapeutics | Nature Reviews Drug Discovery | 2003 | 2,963 |
| 13 | Neurodegenerative diseases and oxidative stress | Nature Reviews Drug Discovery | 2004 | 2,923 |
| 14 | Effect of pegylation on pharmaceuticals | Nature Reviews Drug Discovery | 2003 | 2,920 |
| 15 | The druggable genome | Nature Reviews Drug Discovery | 2002 | 2,918 |
| 16 | Membrane transporters in drug development | Nature Reviews Drug Discovery | 2010 | 2,886 |
| 17 | How to improve R&D productivity: the pharmaceutical industry's grand challenge | Nature Reviews Drug Discovery | 2010 | 2,750 |
| 18 | Modulation of oxidative stress as an anticancer strategy | Nature Reviews Drug Discovery | 2013 | 2,735 |
| 19 | Carbonic anhydrases: novel therapeutic applications for inhibitors and activators | Nature Reviews Drug Discovery | 2008 | 2,702 |
| 20 | Docking and scoring in virtual screening for drug discovery: methods and applications | Nature Reviews Drug Discovery | 2004 | 2,697 |
| 21 | Drug repurposing: progress, challenges and recommendations | Nature Reviews Drug Discovery | 2019 | 2,689 |
| 22 | mRNA vaccines — a new era in vaccinology | Nature Reviews Drug Discovery | 2018 | 2,668 |
| 23 | Knocking down barriers: advances in siRNA delivery | Nature Reviews Drug Discovery | 2009 | 2,639 |
| 24 | Anticancer activities of histone deacetylase inhibitors | Nature Reviews Drug Discovery | 2006 | 2,578 |
| 25 | Extracellular vesicles: biology and emerging therapeutic opportunities | Nature Reviews Drug Discovery | 2013 | 2,563 |
| 26 | Drug repositioning: identifying and developing new uses for existing drugs | Nature Reviews Drug Discovery | 2004 | 2,460 |
| 27 | Design and development of polymers for gene delivery | Nature Reviews Drug Discovery | 2005 | 2,279 |
| 28 | Targeting the phosphoinositide 3-kinase pathway in cancer | Nature Reviews Drug Discovery | 2009 | 2,218 |
| 29 | Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer | Nature Reviews Drug Discovery | 2004 | 2,211 |
| 30 | Understanding biofilm resistance to antibacterial agents | Nature Reviews Drug Discovery | 2003 | 2,180 |
| 31 | Drugs for bad bugs: confronting the challenges of antibacterial discovery | Nature Reviews Drug Discovery | 2007 | 2,180 |
| 32 | The nitrate–nitrite–nitric oxide pathway in physiology and therapeutics | Nature Reviews Drug Discovery | 2008 | 2,084 |
| 33 | The evolving role of natural products in drug discovery | Nature Reviews Drug Discovery | 2005 | 2,028 |
| 34 | Approaches to treat immune hot, altered and cold tumours with combination immunotherapies | Nature Reviews Drug Discovery | 2019 | 2,005 |
| 35 | Natural products in drug discovery: advances and opportunities | Nature Reviews Drug Discovery | 2021 | 1,990 |
| 36 | The influence of drug-like concepts on decision-making in medicinal chemistry | Nature Reviews Drug Discovery | 2007 | 1,969 |
| 37 | Angiogenesis: an organizing principle for drug discovery? | Nature Reviews Drug Discovery | 2007 | 1,960 |
| 38 | Protein kinases — the major drug targets of the twenty-first century? | Nature Reviews Drug Discovery | 2002 | 1,944 |
| 39 | The re-emergence of natural products for drug discovery in the genomics era | Nature Reviews Drug Discovery | 2015 | 1,891 |
| 40 | Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery | Nature Reviews Drug Discovery | 2005 | 1,853 |
| 41 | Aptamers as therapeutics | Nature Reviews Drug Discovery | 2010 | 1,780 |
| 42 | Trends in GPCR drug discovery: new agents, targets and indications | Nature Reviews Drug Discovery | 2017 | 1,773 |
| 43 | The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics | Nature Reviews Drug Discovery | 2011 | 1,766 |
| 44 | Metabonomics: a platform for studying drug toxicity and gene function | Nature Reviews Drug Discovery | 2002 | 1,739 |
| 45 | Peroxynitrite: biochemistry, pathophysiology and development of therapeutics | Nature Reviews Drug Discovery | 2007 | 1,732 |
| 46 | Protein therapeutics: a summary and pharmacological classification | Nature Reviews Drug Discovery | 2008 | 1,678 |
| 47 | Cyclodextrin-based pharmaceutics: past, present and future | Nature Reviews Drug Discovery | 2004 | 1,636 |
| 48 | Hydrogen sulphide and its therapeutic potential | Nature Reviews Drug Discovery | 2007 | 1,614 |
| 49 | A comprehensive map of molecular drug targets | Nature Reviews Drug Discovery | 2017 | 1,608 |
| 50 | Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities | Nature Reviews Drug Discovery | 2008 | 1,585 |
